The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Official Title: Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)
Study ID: NCT03417154
Brief Summary: This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a randomized pilot sub-study during stage 1.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Name: Fiona He, MD
Affiliation: Division of Hematology, Oncology and Transplantation, Masonic Cancer Center
Role: PRINCIPAL_INVESTIGATOR